Janus Henderson Group’s Ascendis Pharma A/S ASND Stock Holding History

Janus Henderson Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,061,641	Closed	-$866M	–	2411
2025 Q4	$866M	Sell	4,061,641 -261,418	-6%	-$54M	0.39%	51
2025 Q3	$859M	Sell	4,323,059 -104,733	-2%	-$19.5M	0.39%	47
2025 Q2	$764M	Sell	4,427,792 -59,157	-1%	-$9.64M	0.37%	54
2025 Q1	$694M	Buy	4,486,949 +106,567	+2%	+$15.2M	0.38%	50
2024 Q4	$603M	Buy	4,380,382 +193,688	+5%	+$25.5M	0.31%	71
2024 Q3	$625M	Buy	4,186,694 +267,881	+7%	+$36.2M	0.32%	70
2024 Q2	$534M	Buy	3,918,813 +151,610	+4%	+$20.6M	0.29%	83
2024 Q1	$569M	Sell	3,767,203 -227,582	-6%	-$32.5M	0.31%	78
2023 Q4	$503M	Buy	3,994,785 +140,252	+4%	+$14M	0.3%	85
2023 Q3	$361M	Sell	3,854,533 -26,829	-0.7%	-$2.51M	0.24%	111
2023 Q2	$346M	Buy	3,881,362 +348,532	+10%	+$30.3M	0.22%	117
2023 Q1	$379M	Sell	3,532,830 -111,125	-3%	-$12.7M	0.25%	101
2022 Q4	$445M	Sell	3,643,955 -4,029,561	-53%	-$468M	0.32%	79
2022 Q3	$792M	Buy	7,673,516 +3,812,257	+99%	+$361M	0.3%	82
2022 Q2	$359M	Buy	3,861,259 +445,732	+13%	+$42M	0.25%	110
2022 Q1	$401M	Buy	3,415,527 +195,562	+6%	+$22.6M	0.19%	126
2021 Q4	$433M	Sell	3,219,965 -31,702	-1%	-$4.72M	0.18%	136
2021 Q3	$518M	Buy	3,251,667 +124,496	+4%	+$17M	0.23%	108
2021 Q2	$411M	Sell	3,127,171 -40,141	-1%	-$5.35M	0.18%	134
2021 Q1	$408M	Buy	3,167,312 +158,483	+5%	+$24.1M	0.19%	123
2020 Q4	$502M	Buy	3,008,829 +42,223	+1%	+$6.98M	0.23%	102
2020 Q3	$458M	Buy	2,966,606 +541,918	+22%	+$77.9M	0.24%	95
2020 Q2	$359M	Buy	2,424,688 +557,498	+30%	+$76.5M	0.2%	115
2020 Q1	$210M	Buy	1,867,190 +614,186	+49%	+$79.8M	0.14%	155
2019 Q4	$174M	Buy	1,253,004 +926,762	+284%	+$103M	0.09%	249
2019 Q3	$31.4M	Buy	+326,242	New	+$36.4M	0.02%	717
2017 Q3	–	Sell	-554,865	Closed	-$15.4M	–	1289
2017 Q2	$15.4M	Buy	+554,865	New	+$14.7M	0.01%	794

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group's ASND Position: Q1 2026 in Review

Janus Henderson Group sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 4,061,641 shares — an estimated $866M sold.

Janus Henderson Group first reported a position in ASND in Q2 2017 and held it in 27 quarters. The position peaked at $866M in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Janus Henderson Group reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Janus Henderson Group sold 4,061,641 Ascendis Pharma A/S shares in Q1 2026, an estimated $866M.
Janus Henderson Group first reported a position in Ascendis Pharma A/S in Q2 2017 and held it in 27 quarters.
Janus Henderson Group's Ascendis Pharma A/S position peaked at $866M in Q4 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.